AGMB · AgomAb Therapeutics NV
Market Cap
$433.38M
Shares
49.25M
Volume · Oct 20
17.09K
Avg daily vol (3M)
137.42K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$8.23
Open$8.28
Day$8.16–8.61
Available close range$8.23–17.82
Avg vol 30d151K
Short int1.0M · 2.0% float · 7.1d
Short vol51%
DataFeb 2026–Oct 2026
The closing range uses available history since Feb 6, 2026; less than a full year is stored.
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
2.0%
Latest settlement · 7.1 days to cover
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 18.4 · elevated
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
Price vs 50-day avg
−31%
below
RSI (14)
30
oversold
MACD trend
Positive
52-week position
0%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−30%
trailing
6-month return
−23%
trailing
Relative strength
−30%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Accumulating
2 of 34 funds reported for Sep 30 · net +52 sh shares
Insider flow
Accumulating
Net +$311.2K over 90 days · 0% sells
Short interest
Rising
2.03% of float · ▲ +15.4% MoM · 7.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
34 holders — 13F breadth
Squeeze score
56
elevated · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
92%
annualized · 1-yr
Max drawdown
−54%
past year
ATR
10.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 50-day avg
−31%
Bearish
RSI (14)
30
Neutral
MACD trend
Positive
Bullish
52-week position
0%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Accumulating
2 of 34 funds reported for Sep 30 · net +52 sh shares
Insider flow
Accumulating
Net +$311.2K over 90 days · 0% sells
Short interest
Rising
2.03% of float · ▲ +15.4% MoM · 7.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
34 holders — 13F breadth
Price context
position in its available closing range
Range low $8
Now $8 · 0%
Range high $18
vs 50-day avg -31%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
AGMB
this stock
AgomAb Therapeutics NV
|
$433.38M | — | — | — | 2.0% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$130.07B | +10.7% | +46.2% | 29.9 | 1.8% |
|
MRNA
Moderna, Inc.
|
$90.58B | +669.4% | +4.3% | — | 7.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$80.51B | +1.3% | +20.8% | 19.4 | 2.1% |
|
CSLLY
Csl Ltd
|
$64.50B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| AGMB | -9.5% | -29.7% | -22.7% | -25.9% | — |
| SPY | -1.5% | -0.9% | +7.7% | +0.5% | +12.4% |
| vs SPY | -8.0% | -28.8% | -30.4% | -26.4% | — |